High-level results from the DESTINY-Breast09 Phase III trial for patients living with HER2+ mBC – AstraZeneca
AstraZeneca shared a post on LinkedIn:
“This post is intended for a US audience.
This week, in collaboration with Daiichi Sankyo, we announced high-level results from our DESTINY-Breast09 Phase III trial for patients living with HER2-positive metastatic breast cancer who have not received chemotherapy or a prior anti-HER2-based regimen in the metastatic setting.
HER2-positive metastatic breast cancer is an aggressive disease driven by high levels of HER2 expression, often associated with poor prognosis. New options are needed that can help improve outcomes for patients with this type of breast cancer early in the course of their disease.
Learn more about these results.”
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared this post, adding:
“Exciting news today for breast cancer.
The first-line treatment landscape for HER2-positive metastatic breast cancer is about to change.”
More posts featuring AstraZeneca and Heidi Ko.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023